ArticlePloS one2014
Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men.Pharmaceutical biology · 2017Trial
- The remote effects of intravitreal anti-VEGF therapy.Journal of medicine and lifeTrial
- Preclinical evaluation of waste-derived pomegranate extract (PWE) as a potential preventing and therapeutic agent for benign prostatic hyperplasia.Frontiers in molecular biosciences · 2026Article
- Drug therapy problems and associated factors among adult patients admitted to the surgical ward in a resource-limited setting.Frontiers in pharmacology · 2025Article
- Evaluation of the Antioxidant and Antiangiogenic Activity of a Pomegranate Extract in BPH-1 Prostate Epithelial Cells.International journal of molecular sciences · 2023Article
- Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.JAMA network open · 2022Article
- Drug-related problems in hospitalised Parkinson's disease patients in China.European journal of hospital pharmacy : science and practice · 2022Article
- Drug-related problems and determinants among elective surgical patients: A prospective observational study.SAGE open medicine · 2022Article
- Standardized Seed Extract ofPreventive nutrition and food science · 2019Article
- 6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis.BMB reports · 2019Article
- Drug-related problems in patients with rheumatoid arthritis.Therapeutics and clinical risk management · 2019Article
- Herbal medicine for benign prostatic hyperplasia: A protocol for a systematic review of controlled trials.Medicine · 2019Article
- Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.Gynecologic oncology research and practice · 2017Article
- Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study.BMJ open · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign Prostatic Hyperplasia (BPH) patients are at risk of acquiring drug-related problems (DRPs), as it is present in the majority of aging men. To date, DRPs among BPH patients have not been well studied. We conducted this retrospective study in a tertiary hospital in Malaysia from January 2009 to June 2012 with the aim of identifying the factors associated with DRPs among BPH patients. The Pharmaceutical Care Network Europe Classification Version (PCNE) 5.01 was used as a tool to classify DRPs. We enrolled 203 patients from 259 hospital admissions. A total of 390 DRPs were found and there was an average of 1.5±1.3 problems per hospitalization. 76.1% of hospital admissions included at least one DRP. The most common DRP categories encountered were drug choice problems (45.9%), drug interactions (24.9%), and dosing problems (13.3%). Factors such as advanced age (p = 0.005), a hospital stay of more than 6 days (p = 0.001), polydrug treatments (p<0.001), multiple comorbidities (p<0.001), and comorbid cardiovascular disease (p = 0.011), diabetes mellitus(p = 0.001), hypertension (p<0.001) and renal impairment (p = 0.011) were significantly associated with the occurrence of DRPs. These data indicated that the prevalence of DRPs is high among BPH patients. The identification of different subtypes of DRPs and the factors associated with DRPs may facilitate risk reduction for BPH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.